Today: 2 June 2026
Browse Category

Pharmaceuticals 11 March 2026 - 24 April 2026

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron Stock Is Back In Focus: Why Wall Street Sees More Upside After Trump Deal

Regeneron shares rose 2.6% Thursday after the company announced a U.S. drug-pricing agreement and said it would offer its new Otarmeni gene therapy free in the U.S. The stock closed at $766.02, up for the week and month but down 1.3% year to date. Raymond James and Cantor Fitzgerald reiterated bullish ratings and high price targets ahead of first-quarter results due April 29.
24 April 2026
··
Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.
23 April 2026
···
Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health shares fell 1.6% to $30.52 Tuesday after Amazon launched a GLP-1 weight-management program through One Medical, intensifying competition in telehealth weight loss. Amazon said its program will offer same-day pharmacy delivery in nearly 3,000 cities and 24/7 prescription renewals. Eli Lilly and Novo Nordisk shares also declined. Hims is shifting away from compounded GLP-1s toward branded, FDA-approved drugs.
21 April 2026
·····
Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly will acquire Boston-based Kelonia Therapeutics for up to $7 billion in cash, including $3.25 billion upfront, to expand into in vivo CAR-T cancer therapies. Kelonia’s KLN-1010, in Phase 1 for multiple myeloma, generates engineered T-cells inside the patient. The deal marks Lilly’s third Massachusetts biotech purchase in 2026. Kelonia had 62 employees and nearly ran out of cash before the offer.
21 April 2026
··
Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

Pfizer Stock in Focus After FDA Priority Review as Padcev, Obesity Bets Drive Post-COVID Reset

The FDA granted priority review to Pfizer and Astellas’ Padcev for muscle-invasive bladder cancer, setting an Aug. 17 decision date. Pfizer shares rose 0.8% to $27.78 after the news. The company reports first-quarter results May 5, with investors watching oncology and obesity drugs to offset declining COVID sales and loss of exclusivity on older products.
20 April 2026
··
Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson Earnings Beat Estimates, J&J Raises 2026 Outlook Despite Stelara Slump

Johnson & Johnson reported first-quarter revenue of $24.1 billion, up 9.9%, and adjusted earnings of $2.70 per share, both above analyst estimates. Sales of cancer drug Darzalex hit $4 billion, while Stelara fell 60% to $656 million. The company raised its 2026 outlook, nudging full-year sales guidance to $100.8 billion. J&J shares slipped 0.27% to $237.96 in early trading.
14 April 2026
···
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal

Soleno Therapeutics withdrew its European filing for VIOKAT on Tuesday, halting a regulatory review that was expected to conclude in 2026. The move came one day after Neurocrine Biosciences agreed to acquire Soleno for $2.9 billion in cash, or $53 a share. Vykat XR, Soleno’s only marketed product, generated $190.4 million in 2025 U.S. sales. Neurocrine said it has no immediate plans for a European launch.
7 April 2026
···
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Neurocrine Biosciences will acquire Soleno Therapeutics for $53 a share in cash, valuing Soleno at $2.9 billion. The deal gives Neurocrine Vykat XR, the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome. Soleno shares last traded at $52.25. The transaction is expected to close within 90 days, pending regulatory and shareholder approval.
7 April 2026
···
Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Pfizer Stock Faces Fresh Questions as Aberdeen, Stratos and Raab & Moskowitz Trim Stakes

Aberdeen Group, Raab & Moskowitz Asset Management, and Stratos Wealth Partners sold a combined 740,174 Pfizer shares in the fourth quarter, according to recent 13F filings. Pfizer stock traded down 0.7% at $28.12 Monday. The three firms still held about $140.9 million in Pfizer shares at year-end. Pfizer halted a major U.S. COVID shot study after the period covered by the filings.
6 April 2026
··
Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli

Biogen agreed to buy Apellis Pharmaceuticals for $5.6 billion, offering $41 per share in cash plus sales-based rights tied to the eye drug Syfovre. Apellis shares traded at $40.23 after the announcement. The deal includes a contingent value right worth up to $4 if Syfovre hits certain sales milestones. Apellis’ board and key shareholders, holding 14%, backed the offer, which is expected to close in the second quarter.
1 April 2026
···
Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Is Pfizer Stock a Buy? Shares Hit Fresh High as Bulls and Bears Clash Over Valuation

Pfizer shares hit a 52-week high of $28.30 in New York Tuesday, lifted by recent drug pipeline updates and strong fourth-quarter sales. The company reported Q4 revenue of $17.56 billion and reaffirmed 2026 guidance. Some analysts remain cautious, with Acquirer’s Multiple valuing shares at $14–$15. Recent trial data showed positive results for Talzenna in prostate cancer and atirmociclib in breast cancer.
31 March 2026
··
Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly secured a global licensing and research deal with Insilico Medicine worth up to $2.75 billion, including $115 million upfront. Lilly’s shares closed Friday at $878.24, down 2.1%. The company also reported positive late-stage results for Taltz with Zepbound in psoriatic arthritis and for eczema drug Ebglyss. Novo Nordisk launched a rival oral obesity pill in the U.S. earlier this month.
29 March 2026
··
Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta

Vertex Pharmaceuticals Stock Falls 4.6% After FDA Label Warning Hits Alyftrek, Trikafta

Vertex Pharmaceuticals shares fell 4.6% to $433.07 Friday after updated U.S. safety warnings on its cystic fibrosis drugs Alyftrek and Trikafta cited reports of serious neuropsychiatric events. The new labels advise close monitoring for symptoms such as depression and suicidal thoughts. Vertex expects 2026 revenue to remain heavily dependent on cystic fibrosis treatments, despite ongoing efforts to expand its pipeline.
28 March 2026
··
Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals (TERN) Stock Holds Near Merck’s $53 Offer After $6.7 Billion Buyout

Terns Pharmaceuticals shares traded at $52.86 in U.S. premarket Thursday, just below Merck’s $53-per-share cash offer after Merck agreed to acquire the company for about $6.7 billion. The deal centers on Terns’ leukemia drug TERN-701, which showed a 75% major molecular response rate in early trials. The offer requires over 50% of shares tendered and antitrust approval. Terns would owe Merck $235 million if it accepts a higher bid.
26 March 2026
···
Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck to Buy Terns Pharmaceuticals for $6.7 Billion to Boost Cancer Pipeline as Keytruda Patent Expiry Nears

Merck will acquire Terns Pharmaceuticals for $53 per share in cash, valuing the company at about $6.7 billion. The deal gives Merck rights to TERN-701, an experimental leukemia drug, as it prepares for Keytruda’s patent expirations in 2028. The offer represents a 6% premium to Terns’ last close and is subject to antitrust review and shareholder approval. Merck expects to close the transaction in the second quarter.
25 March 2026
··
Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk Stock Price Slips Even After FDA Clears High-Dose Wegovy

Novo Nordisk shares fell 1.5% in Copenhagen Thursday despite FDA approval of a higher-dose Wegovy shot. Shares stayed down as Eli Lilly released new obesity drug data and Reuters reported India’s semaglutide patent expiry will allow cheaper generics. Novo expects to launch the 7.2-mg Wegovy in the U.S. in April. Over 40 Indian drugmakers are preparing generic versions as prices are set to drop.
20 March 2026
··
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly said its obesity and diabetes drug candidate retatrutide met main goals in a late-stage trial, cutting A1C by up to 2% and body weight by 16.8%. Shares traded at $918.05, down 1.3% after an HSBC downgrade and concerns over U.S. price cuts. Side effects included nausea and vomiting, with a 5.1% discontinuation rate at the highest dose. Detailed results will be presented in June.
19 March 2026
···
Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer shares closed down 1% at $26.60 Friday after GSK’s RSV vaccine won expanded FDA approval for at-risk adults 18 to 49, narrowing Pfizer’s lead in the RSV market. Positive trial data for Pfizer’s blood thinner Eliquis offset some pressure, but the stock finished near session lows amid broader market weakness and uncertainty over the company’s near-term growth outlook.
13 March 2026
···
Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer shares fell 1.6% to $26.86 Thursday amid a broad U.S. market selloff as oil prices rose on Middle East tensions. The company faces pressure from declining COVID product sales and forecast 2026 profit below Wall Street estimates. China approved Pfizer’s GLP-1 weight-loss drug last week, while rival Eli Lilly announced a $3 billion China investment. Pfizer lost a legal bid in generic-drug litigation this week.
12 March 2026
···
1 2 3 4 5 … 41

Latest articles

Swarmer Soars 38% After Cramer Shouts Out Drone Software

Swarmer Soars 38% After Cramer Shouts Out Drone Software

2 June 2026
Swarmer soared 37.7% to $78.52 after Jim Cramer called it “a natural” on “Mad Money,” sparking retail and drone investor interest despite shrinking revenue, widening losses, and execution risks around defense contracts; shares now trade over 15 times their March IPO price.
Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

2 June 2026
Abivax shares plunged 44% to €63.10 after strong Phase 3 results for obefazimod in ulcerative colitis were overshadowed by cancer and dysplasia cases in the high-dose arm, which investigators deemed unrelated to treatment, raising investor concerns over safety and regulatory risk despite meeting all efficacy endpoints.
Netflix Stock Sinks, Wall Street Turns to June 4

Netflix Stock Sinks, Wall Street Turns to June 4

2 June 2026
Netflix shares slid nearly 3% to $83.36 as investors questioned growth targets ahead of Thursday’s annual meeting, with the stock under pressure despite management maintaining 2026 revenue and margin forecasts and warning of heavier content costs in the first half.
Marathon Digital Drops as Bitcoin Tops $70,000; Eyes on AI Push

Marathon Digital Drops as Bitcoin Tops $70,000; Eyes on AI Push

2 June 2026
MARA fell 4.2% to $14.23 as bitcoin slid below $70,000, highlighting the miner’s ongoing dependence on crypto prices despite efforts to pivot toward AI and power infrastructure; analysts remain split on the new strategy, and the Long Ridge deal still faces regulatory and execution risks.
Dow, S&P inch up as AI surge faces $80 billion hurdle

Dow, S&P inch up as AI surge faces $80 billion hurdle

2 June 2026
Alphabet shares fell after announcing plans to raise $80 billion through equity offerings to fund soaring AI infrastructure costs, even as demand for its AI services exceeded supply and capital spending forecasts climbed to $180–$190 billion for 2026.
Go toTop